Skip to main content

Table 1 Baseline characteristics by MDA responder (−R) or non-responder (-NR) status and overall

From: Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Measure MDA-R (N = 157) MDA-NR (N = 326) Total (N = 483) p-value
Age, mean (SD) 48.2 (13.7) 52.1 (10.8) 50.8 (12.0) 0.002
Female gender, n (%) 68 (43.3) 192 (58.9) 260 (53.8) 0.001
Race, n (%) 0.121
 White 143 (91.1) 307 (94.5) 450 (93.4)  
 Asian 8 (5.1) 13 (4.0) 21 (4.4)  
 Other 6 (3.8) 5 (1.5) 11 (2.3)  
 Weight kg, mean (SD) 81.1 (17.3) 88.1 (21.2) 85.9 (20.3) < 0.001
 BMI kg/m2, mean (SD) 27.7 (5.1) 31.0 (7.6) 30.0 (7.0) < 0.001
 Time since PsA onset, mean years (SD) 10.5 (9.3) 11.2 (8.9) 11.0 (9.0) 0.51
 Time since PsA diagnosis, mean years (SD) 7.7 (7.8) 8.5 (7.8) 8.2 (7.8) 0.63
 CASPAR score, mean (SD) 4.4 (1.0) 4.4 (0.9) 4.4 (0.9) 0.96
 Curr. enthesitis, n (%) 78 (50.0) 200 (61.7) 278 (57.9) 0.017
 Curr. dactylitis, n (%) 47 (30.1) 63 (19.4) 110 (22.9) 0.027
 Curr. psoriasis, n (%) 149 (94.9) 304 (93.3) 453 (93.8) 0.46
 PASI total scorea, mean (SD) 6.3 (6.6) 6.1 (8.0) 6.2 (7.5) 0.77
 cDMARD at baseline, n (%) 93 (59.2) 194 (59.5) 287 (59.4) 0.74
 Methotrexate at baseline, n (%) 77 (49.0) 156 (47.9) 233 (48.2) 0.98
  1. aFor patients with plaque psoriasis. Abbreviations, BMI = body mass index, CASPAR = classification of psoriatic arthritis; cDMARD = conventional disease-modifying antirheumatic drug; curr. = current, MDA = minimal disease activity, NR = non-responder, N = number of patients in the analysis population, n = number of patients in each subgroup, PASI = psoriasis area and severity index, PsA = psoriatic arthritis, −R = responder, SD = standard deviation